AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7952921 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte transformation assay for serovar B
Number of subjects: 20
Study 7952921 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte transformation assay for serovar C
Number of subjects: 20
Study 7952921 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte migration inhibition assay for serovar B
Number of subjects: 20
Study 7952921 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte migration inhibition assay for serovar C
Number of subjects: 20
Study 3597861 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat tenderizer containing the proteolytic enzyme papain
Number of subjects: 22
Study 3597861 — intervention group
Group type: COMPARATOR
Intervention: Control (stings treated without tenderizer)
Number of subjects: 22
Study 29664721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive compression
Number of subjects: 26
Study 29664721 — intervention group
Group type: COMPARATOR
Intervention: Fast-acting WDRC
Number of subjects: 26
Study 27017501 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided design of navigation template (NT)
Number of subjects: 36
Study 27017501 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramedullary positioning (CIP)
Number of subjects: 36
Study 26703671 — intervention group
Group type: EXPERIMENTAL
Intervention: Church-based educational intervention (three educational sessions about clinical trials and health disparities)
Number of subjects: 221
Study 26703671 — intervention group
Group type: COMPARATOR
Intervention: Control (questionnaires)
Number of subjects: 221
Study 26703671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 221
Study 26703671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study 23614393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg twice daily on days 1-9 with a single 25 mg dose of warfarin coadministered on day 3
Number of subjects: 16
Study 23614393 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone (25 mg)
Number of subjects: 16
Study 20429947 — intervention group
Group type: EXPERIMENTAL
Intervention: Online treatment program for GAD, E‐couch
Number of subjects: 120
Study 20429947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25-100 mg/day)
Number of subjects: 120
Study 20429947 — intervention group
Group type: COMPARATOR
Intervention: Attention control placebo, HealthWatch
Number of subjects: 120
Study 18241758 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 3580
Study 18241758 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 3580
Study 17014445 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dewaxing
Number of subjects: 100
Study 17014445 — intervention group
Group type: COMPARATOR
Intervention: Microscopic dewaxing
Number of subjects: 100
Study 14613288 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly for 24 weeks
Number of subjects: 277
Study 14613288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 14613288 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 277
Study 10776742 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 137
Study 10776742 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin
Number of subjects: 137
Study 10776742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 8601640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion (27 microgram over 100 min) during normoglycemic hyperinsulinemic conditions
Number of subjects: 12
Study 8601640 — intervention group
Group type: COMPARATOR
Intervention: Control leg during normoglycemic hyperinsulinemic conditions
Number of subjects: 12
Study 8601640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion (27 microgram over 100 min) in the basal state
Number of subjects: 12
Study 1449383 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 25
Study 1449383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3879175 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen syrup (5-7.5 mg/kg b.w., orally)
Number of subjects: 175
Study 3879175 — intervention group
Group type: COMPARATOR
Intervention: L PDP ear drops (1 drop, locally)
Number of subjects: 175
Study 30056451 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resin denture with 20wt% S-PRG fillers
Number of subjects: 110
Study 30056451 — intervention group
Group type: COMPARATOR
Intervention: Partial resin denture without 20wt% S-PRG fillers
Number of subjects: 110
Study 27749377 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (details on dosage and duration not specified)
Number of subjects: 250
Study 27382934 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous hyoscine-N-butylbromide
Number of subjects: 121
Study 27382934 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline solution (placebo)
Number of subjects: 121
Study 25198222 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight‐bearing exercise program for 20 weeks
Number of subjects: 22
Study 25198222 — intervention group
Group type: COMPARATOR
Intervention: Regular activities
Number of subjects: 22
Study 21701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Number of subjects: 12274
Study 21701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups
Number of subjects: 12274
Study 21701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index (CCI)
Number of subjects: 12274
Study 21701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference table for predicting POM
Number of subjects: 12274
Study 20363190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 84
Study 20363190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17593071 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mol/L hydrochloric acid infusion (150 mL at 15 mL/min for 10 min)
Number of subjects: 27
Study 17593071 — intervention group
Group type: COMPARATOR
Intervention: Pure water infusion (150 mL)
Number of subjects: 27
Study 15670425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer prevention intervention
Number of subjects: 197
Study 11549532 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol dry powder 12 or 24 microg twice daily
Number of subjects: 780
Study 11549532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microg four times daily
Number of subjects: 780
Study 11549532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 9512150 — intervention group
Group type: EXPERIMENTAL
Intervention: One-site combined trabeculectomy and phacoemulsification
Number of subjects: 33
Study 9512150 — intervention group
Group type: COMPARATOR
Intervention: Two-site combined trabeculectomy and phacoemulsification
Number of subjects: 33
Study 7832009 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy with positive alcohol beliefs
Number of subjects: 72
Study 7832009 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy with negative alcohol beliefs
Number of subjects: 72
Study 7832009 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who expected alcohol with positive beliefs
Number of subjects: 72
Study 7832009 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who expected tonic
Number of subjects: 72
Study 7832009 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure behavior
Number of subjects: 72
Study 3415801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg every 12 hours)
Number of subjects: 12
Study 3415801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29297958 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel)
Number of subjects: 32
Study 29297958 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroxyethyl cellulose gel alone (placebo)
Number of subjects: 32
Study 29297958 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied clobetasol propionate 0.05%
Number of subjects: 32
Study 26924818 — intervention group
Group type: EXPERIMENTAL
Intervention: Axomadol (doses ranging from 66 mg to 225 mg)
Number of subjects: 74
Study 26924818 — intervention group
Group type: EXPERIMENTAL
Intervention: RR O‐demethyl metabolite
Number of subjects: 74
Study 26924818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 26285662 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute simvastatin treatment
Number of subjects: 102
Study 23659755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 300 mg
Number of subjects: 311
Study 23659755 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 311
Study 23659755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg
Number of subjects: 311
Study 23659755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin groups
Number of subjects: 311
Study 23659755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin combined with EVR
Number of subjects: 311
Study 20944175 — intervention group
Group type: EXPERIMENTAL
Intervention: CDET imaging (group B)
Number of subjects: 69
Study 20944175 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging (group A)
Number of subjects: 69
Study 18162661 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrogance disclaimer
Number of subjects: 0
Study 18162661 — intervention group
Group type: EXPERIMENTAL
Intervention: Laziness disclaimer
Number of subjects: 0
Study 18162661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selfishness disclaimer
Number of subjects: 0
Study 18162661 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclaimers in general
Number of subjects: 0
Study 16608770 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (Inmunoferon)
Number of subjects: 16
Study 16608770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12755654 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 40
Study 12755654 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 40
Study 15504993 — intervention group
Group type: COMPARATOR
Intervention: Physical activity >2.5 h/week
Number of subjects: 8299
Study 15504993 — intervention group
Group type: COMPARATOR
Intervention: TV viewing >14 h/week
Number of subjects: 8299
Study 10030327 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 42
Study 10030327 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 42
Study 7559885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GHRP-2
Number of subjects: 24
Study 7559885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GHRP-2 (5-20 micrograms/kg per dose)
Number of subjects: 24
Study 7559885 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2 (administered simultaneously)
Number of subjects: 24
Study 7559885 — intervention group
Group type: COMPARATOR
Intervention: Conventional agents (arginine, L-dopa/exercise, insulin)
Number of subjects: 24
Study 2251986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1067
Study 7197960 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (492 mg quinidine-base as quinidine-bisulfate)
Number of subjects: 0
Study 7197960 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine formulation 1
Number of subjects: 0
Study 7197960 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine formulation 2
Number of subjects: 0
Study 28334675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=22)
Number of subjects: 42
Study 28334675 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=20)
Number of subjects: 42
Study 25987642 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.006 mg/Kg)
Number of subjects: 12
Study 25987642 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 12
Study 22948968 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 30 mg/m²
Number of subjects: 743
Study 22948968 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin 30 mg/m²
Number of subjects: 743
Study 22948968 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin 40 mg/m²
Number of subjects: 743
Study 20213082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 334
Study 19835126 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) without mechanical pressure
Number of subjects: 20
Study 19835126 — intervention group
Group type: COMPARATOR
Intervention: Mechanical pressure of 1 kg applied at Ximen (PC 4) during and after acupuncture
Number of subjects: 20
Study 19835126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical pressure at Daling (PC 7) during acupuncture
Number of subjects: 20
Study 19835126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical pressure at Daling (PC 7) after acupuncture
Number of subjects: 20
Study 17172317 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (30-min intervals at 60% of maximum heart rate for 10 weeks)
Number of subjects: 10
Study 17172317 — intervention group
Group type: COMPARATOR
Intervention: Control group (not engaging in regular physical activity)
Number of subjects: 10
Study 14696048 — intervention group
Group type: EXPERIMENTAL
Intervention: RF operators
Number of subjects: 35
Study 11497194 — intervention group
Group type: COMPARATOR
Intervention: Placebo screening
Number of subjects: 140
Study 9762161 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered self-expanding esophageal metal stents (Cook Z Stent and Ultraflex)
Number of subjects: 32
Study 9762161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflex prosthesis
Number of subjects: 32
Study 7836510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen-progestin add-back therapy (0.75 mg oestropipate daily + 0.7 mg norethindrone on days 1-14 each month)
Number of subjects: 51
Study 7836510 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin add-back therapy (10 mg norethindrone daily)
Number of subjects: 51
Study 7836510 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate depot (3.75 mg every 4 weeks for 2 years)
Number of subjects: 51
Study 2972550 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-dergocrine (DA2-agonist)
Number of subjects: 12
Study 2972550 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake (Control)
Number of subjects: 12
Study 31916514 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term ART adherents (≤24 months)
Number of subjects: 3625
Study 31916514 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-term ART adherents (>24 months)
Number of subjects: 3625
Study 31669193 — intervention group
Group type: EXPERIMENTAL
Intervention: AS37-adjuvanted vaccine (TLR7a dose 12.5, 25, 50, 100 μg)
Number of subjects: 80
Study 31669193 — intervention group
Group type: COMPARATOR
Intervention: Control group (licensed MenC conjugate alum-adjuvanted vaccine)
Number of subjects: 80
Study 31669193 — intervention group
Group type: EXPERIMENTAL
Intervention: AS37-adjuvanted vaccine (TLR7a 100 μg)
Number of subjects: 80
Study 28232209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (HG): short‐term pre‐acclimatisation by the use of intermittent hypoxia 7×1h at FiO2=12.6%, equivalent to 4500m
Number of subjects: 52
Study 28232209 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): sham pre‐acclimatisation 7×1h at FiO2=20.9%, equivalent to 600m
Number of subjects: 52
Study 25833032 — intervention group
Group type: EXPERIMENTAL
Intervention: AmED 500 ml energy drink (ED)
Number of subjects: 19
Study 25833032 — intervention group
Group type: EXPERIMENTAL
Intervention: AmED 750 ml energy drink (ED)
Number of subjects: 19
Study 25833032 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 19
Study 25833032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23499420 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-tempo music listening (two 1-hour daily periods)
Number of subjects: 49
Study 23499420 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-tempo music listening
Number of subjects: 49
Study 21301948 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 142
Study 21301948 — intervention group
Group type: COMPARATOR
Intervention: Cancer education intervention
Number of subjects: 142
Study 19680456 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g daily
Number of subjects: 70
Study 19680456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17619598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioners in heart failure management outpatient clinics
Number of subjects: 0
Study 17619598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioners
Number of subjects: 0
Study 14961155 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of antithrombin III (6 vials: 3000 units) once daily for 5 days or until delivery
Number of subjects: 23
Study 14961155 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of antithrombin III (sufficient to maintain at least 80% activity)
Number of subjects: 23
Study 14961155 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of antithrombin III
Number of subjects: 23
Study 14961155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high doses and standard doses)
Number of subjects: 23
Study 12501151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (60 mg/kg/d in 4 doses via nasogastric tube)
Number of subjects: 160
Study 12501151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (2 mg/kg/d intravenously in 4 doses)
Number of subjects: 160
Study 12501151 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (1 mg/kg/d intravenously in 2 doses)
Number of subjects: 160
Study 12501151 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 160
Study 9585041 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar 'best septal' projection
Number of subjects: 32
Study 9585041 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar LPO
Number of subjects: 32
Study 9585041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic radionuclide ventriculography
Number of subjects: 32
Study 7619035 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation rewarming with the Heat Treat
Number of subjects: 8
Study 7619035 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive rewarming with a respiratory heat exchanger (HME)
Number of subjects: 8
Study 7619035 — intervention group
Group type: COMPARATOR
Intervention: Passive rewarming (Control)
Number of subjects: 8
Study 2096602 — intervention group
Group type: EXPERIMENTAL
Intervention: AT877 20 mg
Number of subjects: 113
Study 2096602 — intervention group
Group type: EXPERIMENTAL
Intervention: AT877 40 mg
Number of subjects: 113
Study 2096602 — intervention group
Group type: EXPERIMENTAL
Intervention: AT877 60 mg
Number of subjects: 113
Study 2096602 — intervention group
Group type: EXPERIMENTAL
Intervention: AT877 90 mg
Number of subjects: 113
Study 2096602 — intervention group
Group type: EXPERIMENTAL
Intervention: AT877 120-180 mg
Number of subjects: 113
Study 351537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride (Sudafed)
Number of subjects: 190
Study 351537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 31498375 — intervention group
Group type: COMPARATOR
Intervention: Competition arm (n = 150)
Number of subjects: 602
Study 31498375 — intervention group
Group type: COMPARATOR
Intervention: Support arm (n = 151)
Number of subjects: 602
Study 31498375 — intervention group
Group type: COMPARATOR
Intervention: Collaboration arm (n = 150)
Number of subjects: 602
Study 31498375 — intervention group
Group type: COMPARATOR
Intervention: Competition arm (n = 150) during follow-up
Number of subjects: 602
Study 31498375 — intervention group
Group type: COMPARATOR
Intervention: Support arm (n = 151) during follow-up
Number of subjects: 602
Study 31498375 — intervention group
Group type: COMPARATOR
Intervention: Collaboration arm (n = 150) during follow-up
Number of subjects: 602
Study 29081135 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional mapping
Number of subjects: 79
Study 29081135 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional mapping
Number of subjects: 79
Study 26283657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil
Number of subjects: 0
Study 26283657 — intervention group
Group type: COMPARATOR
Intervention: Low-dose fish oil
Number of subjects: 0
Study 26283657 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PL EPA
Number of subjects: 0
Study 26283657 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PL DHA
Number of subjects: 0
Study 24108314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30-180 mg daily)
Number of subjects: 3883
Study 24108314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study 21723949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose S-ketamine (0.1mg/kg bolus for 5min, continuous infusion of 0.015625mg/kg/min reduced by 10% every ten minutes)
Number of subjects: 24
Study 21723949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21723949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose S-ketamine
Number of subjects: 24
Study 17938924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radial head prosthesis replacement
Number of subjects: 20
Study 17938924 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 20
Study 16442905 — intervention group
Group type: EXPERIMENTAL
Intervention: No coronary artery disease
Number of subjects: 1293
Study 16442905 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic lead II P‐wave duration > 135 milliseconds
Number of subjects: 1293